Chepeleva Elena V
Federal State Budgetary Institution National Medical Research Center Named after Academician E.N. Meshalkin of the Ministry of Health of the Russian Federation, 15, Rechkunovskaya Str., 630055 Novosibirsk, Russia.
Research Institute of Clinical and Experimental Lymphology-Branch of the Institute of Cytology and Genetics Siberian Branch of Russian Academy of Sciences, 2, Timakova Str., 630060 Novosibirsk, Russia.
Int J Mol Sci. 2023 Nov 28;24(23):16844. doi: 10.3390/ijms242316844.
Heart failure is a leading cause of death in patients who have suffered a myocardial infarction. Despite the timely use of modern reperfusion therapies such as thrombolysis, surgical revascularization and balloon angioplasty, they are sometimes unable to prevent the development of significant areas of myocardial damage and subsequent heart failure. Research efforts have focused on developing strategies to improve the functional status of myocardial injury areas. Consequently, the restoration of cardiac function using cell therapy is an exciting prospect. This review describes the characteristics of various cell types relevant to cellular cardiomyoplasty and presents findings from experimental and clinical studies investigating cell therapy for coronary heart disease. Cell delivery methods, optimal dosage and potential treatment mechanisms are discussed.
心力衰竭是心肌梗死患者的主要死因。尽管及时使用了现代再灌注疗法,如溶栓、外科血管重建和球囊血管成形术,但有时仍无法预防大面积心肌损伤的发生及随后的心力衰竭。研究工作集中在制定改善心肌损伤区域功能状态的策略上。因此,利用细胞疗法恢复心脏功能是一个令人兴奋的前景。这篇综述描述了与细胞心肌成形术相关的各种细胞类型的特征,并介绍了研究冠心病细胞疗法的实验和临床研究结果。讨论了细胞递送方法、最佳剂量和潜在的治疗机制。